Physician

John H Niffenegger, MD

According to 2025 Medicare claims, John Niffenegger, MD (NPI: 1518910280) practices ophthalmology in the North Port-Bradenton-Sarasota, FL market, with the plurality of this provider's patient population coming from Sarasota, FL. This provider's primary affiliated billing organization is RETINA VITREOUS CONSULTANTS (NPI: 1699773796; TIN: 592086792) and primary practice location at 33952-8089.

Niffenegger's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,439 traditional Medicare patients, billed 58,964 HCPCS/CPT codes, and received $4,414,546 in Medicare payments. The top billing code was 67028 (Injection of drug into eye). Part D data shows 658 prescription claims across 199 beneficiaries totaling $42,466 in drug costs, led by Lumigan (Bimatoprost). Open Payments data shows 3 records totaling $45. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$2.6M$5.2M2015 Medicare payment: $4,731,697 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $5,204,488 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $4,582,800 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $4,731,403 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $5,070,670 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $5,114,057 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $5,018,980 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $4,922,208 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $4,479,724 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $4,414,546 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,53623,317$4,731,697
20161,57423,618$5,204,488
20171,58021,969$4,582,800
20181,62322,139$4,731,403
20191,71923,603$5,070,670
20201,66721,689$5,114,057
20211,65820,269$5,018,980
20221,68020,998$4,922,208
20231,59941,037$4,479,724
20241,43958,964$4,414,546

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$52K$104K2015 Drug cost: $48,812 (USD; Tot_Drug_Cst)2016 Drug cost: $61,178 (USD; Tot_Drug_Cst)2017 Drug cost: $57,344 (USD; Tot_Drug_Cst)2018 Drug cost: $55,702 (USD; Tot_Drug_Cst)2019 Drug cost: $85,048 (USD; Tot_Drug_Cst)2020 Drug cost: $103,519 (USD; Tot_Drug_Cst)2021 Drug cost: $102,845 (USD; Tot_Drug_Cst)2022 Drug cost: $95,757 (USD; Tot_Drug_Cst)2023 Drug cost: $83,843 (USD; Tot_Drug_Cst)2024 Drug cost: $42,466 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015118386$48,812
2016165520$61,178
2017159471$57,344
2018174516$55,702
2019217805$85,048
2020242985$103,519
20212551,052$102,845
2022259888$95,757
2023217725$83,843
2024199658$42,466

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
67028Injection of drug into eye5702,071$101
92014Established patient complete exam of visual system771963$89
92012Established patient problem focused exam of visual system5651,158$70
92134Imaging of retina1,3403,063$31
92201Extended exam of the back part of the eye with retinal drawing592671$18

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
LumiganBimatoprost15743$6,368
Prednisolone AcetatePrednisolone Acetate1046,725$4,414
SimbrinzaBrinzolamide/Brimonidine Tart14822$3,738
Bromfenac SodiumBromfenac Sodium25888$2,992
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol231,288$2,811

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.3$45Notal Vision, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for John H. Niffenegger, MD?

Tedicare shows public-source Medicare data for John H. Niffenegger, MD (NPI 1518910280), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John H. Niffenegger, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John H. Niffenegger, MD?

John H. Niffenegger, MD is linked to RETINA VITREOUS CONSULTANTS (billing NPI 1699773796) in the available physician profile data.

Does John H. Niffenegger, MD have Open Payments data?

John H. Niffenegger, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.